Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

China fined GlaxoSmithKline Plc a record 3 billion yuan ($489 million) on Friday for paying bribes to doctors to use its drugs, underlining the risks of doing business there while also ending a ...

The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...